A Molecular characterization and virulence profiles of Staphylococcus aureus bloodstream infection and their associations with clinical prognosis: a comparative analysis of MSSA/MRSA and predominant ST188/ST398

In the microscopic world that shares our bodies, Staphylococcus aureus is a common resident. It often lives harmlessly on the skin or in the nose, but when it slips into the bloodstream, it becomes a formidable enemy capable of causing severe, life-threatening illness. Doctors have long known that not all strains of this bacterium are equal. Some are easily treated with standard antibiotics, while others have evolved defenses that make them resistant to multiple drugs, turning a manageable infection into a medical crisis. Beyond just drug resistance, scientists have discovered that different strains also possess unique "toolkits" for attacking the human body. Some strains are better at building protective shields to hide from the immune system, while others are equipped with potent toxins that tear through cells. Understanding exactly how these different strains behave, and how their genetic makeup influences a patient's chance of survival, is critical for doctors trying to choose the right treatment.

A team of researchers at the Affiliated Lihuili Hospital of Ningbo University recently set out to map these differences in a specific region of China. They gathered blood samples from 81 patients who had been admitted to the hospital between January 2021 and December 2025 with a bloodstream infection caused by this bacterium. The team did not just look at which antibiotics worked; they performed a deep genetic analysis of every single bacterial sample. By reading the complete genetic code of each strain, they could identify exactly which family the bacteria belonged to and what specific weapons they carried. They also tested the bacteria in the lab to see how well they could build protective films and how effectively they could destroy red blood cells. This comprehensive approach allowed them to connect the genetic identity of the bacteria directly to the patient's clinical outcome.

The study revealed that two specific genetic families, known as ST188 and ST398, were the most common culprits in this group of patients, together accounting for nearly a third of all cases. A striking difference emerged between these two families. The ST188 group consisted entirely of bacteria that could be killed by methicillin, a standard antibiotic. In contrast, half of the ST398 group had evolved to resist this drug. The researchers found that patients infected with the drug-resistant bacteria had a significantly higher risk of a poor outcome, including death. However, this relationship is complicated by the fact that drug resistance is unevenly distributed across different genetic lineages; in this study, all ST188 isolates were drug-sensitive while half of the ST398 isolates were drug-resistant. This overlap means that the genetic background of the strain confounds the relationship between drug resistance and patient outcomes, making it difficult to separate the independent effects of the two factors.

When the researchers tested the bacteria's ability to form biofilms—sticky, protective layers that help bacteria survive on medical devices and resist the immune system—they found a clear divide based on the genetic family, not the drug resistance. The ST188 bacteria were far better at building these protective films than the ST398 bacteria. Conversely, the ST398 bacteria were much more aggressive in their ability to destroy red blood cells, a measure of how toxic they are to the body's tissues. Interestingly, whether a bacterium was drug-resistant or not did not change these behaviors. The study found no statistically significant difference in biofilm formation or hemolytic activity between the drug-resistant (MRSA) and drug-sensitive (MSSA) groups. This suggests that the bacteria's "personality" is determined more by its genetic lineage than by its resistance to antibiotics.

The genetic analysis provided a deeper look into why these differences exist. The researchers discovered that the drug-resistant bacteria often had lost certain genes that produce specific toxins, while the drug-sensitive strains kept them. Furthermore, the two dominant families carried different sets of toxin genes. The ST398 family, which was more toxic to blood cells, carried a specific cluster of genes associated with high hemolytic activity. The ST188 family, which excelled at building biofilms, carried a different set of genes related to enzymes that help bacteria stick together. The study also noted that the drug-resistant strains within the ST398 family were so genetically similar to their drug-sensitive counterparts that they likely evolved from the same recent ancestor, simply acquiring a resistance gene along the way.

These findings highlight that the battle against this bacterium is not a simple matter of drug resistance versus susceptibility. The genetic background of the infection plays a massive role in how the disease progresses. A patient infected with a drug-sensitive strain from the ST188 family faces a different set of risks than a patient infected with a drug-resistant strain from the ST398 family. The study suggests that to truly understand the danger of an infection, doctors need to look beyond just whether the bacteria can be killed by antibiotics. They must also consider the specific genetic family of the bacteria, as this determines whether the infection will be characterized by stubborn, film-forming persistence or by rapid, toxin-driven tissue damage. By identifying these patterns, medical teams can better predict the course of an illness and tailor their infection control strategies to the specific threats posed by different bacterial lineages.